VERA raised substantial capital as evidenced by a 283% increase in cash to $354.7M, but R&D spending accelerated 71% and net losses nearly doubled to $299.6M.
The massive cash increase suggests a successful equity raise that should extend the company's runway, which is critical given their pre-revenue status and accelerating burn rate. However, the near-doubling of losses and 79% increase in operating cash outflows indicate the company is in a much more expensive phase of development, likely advancing multiple clinical programs simultaneously.
VERA's financial profile shows a company that successfully raised significant capital (cash up 283% to $354.7M) but is now operating at a much higher burn rate with R&D expenses increasing 71% to $215.3M and net losses nearly doubling to $299.6M. Operating cash outflows worsened 79% to $241.1M while debt increased 48% to $74.8M, suggesting the company is funding aggressive clinical development across its pipeline. The substantial cash raise provides runway, but the accelerating losses indicate VERA is in a capital-intensive phase that will require careful monitoring of clinical milestones to justify the increased spending.
Cash position surged 282.9% — strong cash generation or capital raise providing significant financial cushion.
Interest expense surged 281.7% — significant debt increase or rising rates materially impacting earnings.
Current liabilities surged 110.7% — significant near-term obligations; verify ability to meet short-term debt.
Net income declined 96.9% — review whether driven by operations, interest costs, or non-recurring items.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Operating cash flow fell 79% — earnings quality concerns; investigate working capital changes and non-cash items.
R&D investment increased 70.6% — signals commitment to future product development, though near-term margin impact.
Liabilities grew 65.8% — significant increase in debt or obligations, assess impact on financial flexibility.
Debt increased 47.6% — substantial leverage increase; assess whether deployed for growth or covering losses.
Capex reduced 35.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →